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Brown adipose tissue (BAT) has attracted scientific
interest as an antidiabetic tissue owing to its ability
to dissipate energy as heat. Despite a plethora of
data concerning the role of BAT in glucose metabo-
lism in rodents, the role of BAT (if any) in glucose
metabolism in humans remains unclear. To investi-
gate whether BAT activation alters whole-body glu-
cose homeostasis and insulin sensitivity in humans,
we studied seven BAT-positive (BAT+) men and five
BAT-negative (BAT2) men under thermoneutral con-
ditions and after prolonged (5–8 h) cold exposure
(CE). The two groups were similar in age, BMI, and
adiposity. CE significantly increased resting energy
expenditure, whole-body glucose disposal, plasma
glucose oxidation, and insulin sensitivity in the BAT+
group only. These results demonstrate a physio-
logically significant role of BAT in whole-body
energy expenditure, glucose homeostasis, and insu-
lin sensitivity in humans, and support the notion that
BAT may function as an antidiabetic tissue in
humans.
Diabetes mellitus currently affects 25.8 million Americans
(1). Obesity, which typically precedes diabetes, results in
altered glucose control. Indeed, adiposity has been impli-
cated in the etiology of insulin resistance, where lipid
moieties from the white adipose tissue (WAT) depots dis-
rupt insulin signaling.
Adult humans have recently been shown to have
brown adipose tissue (BAT) (2–4). Further, BAT is asso-
ciated with leanness (5) and euglycemia (4,6,7), suggest-
ing that, unlike other adipose tissue depots, BAT may be
protective against obesity and diabetes. The unique fea-
ture of BAT that explains the proposed effects on obesity
and glucose control is the abundance of mitochondria,
which contain uncoupling protein 1 (UCP1). UCP1
uncouples oxidative phosphorylation by allowing pro-
tons to re-enter the mitochondrial matrix independent
of ATP synthase, producing heat instead of chemical
energy (8). Rodent studies show that, upon stimulation,
BAT uses glucose and free fatty acids (FFAs) for thermo-
genesis (8), confirming the regulatory role of BAT in
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adiposity, glucose homeostasis, and insulin sensitivity
(9,10).
The physiological significance of BAT activation in
whole-body substrate metabolism in humans remains un-
clear. Orava et al. (11) reported that cold exposure (CE)
resulted in a 12-fold increase in glucose disposal in BAT,
but not in other tissues. Ouellet et al. (12) reported similar
results. This suggests that, upon activation, BAT clears
plasma glucose. However, these investigators did not
show differences in whole-body insulin-stimulated glucose
disposal between individuals with detectable BAT (BAT+) or
nondetectable BAT (BAT2), questioning the ability of BAT
to modulate whole-body glucose metabolism. Similarly,
Ouellet et al. (12) recently showed that under short-term
CE, BAT primarily oxidizes intracellular fatty acids; plasma
substrate oxidation by BAT was minimal (12).
The results from the aforementioned studies question
the role of BAT in whole-body metabolism in humans.
However, Orava et al. (11,13) compared whole-body
insulin-stimulated glucose disposal between BAT+ and BAT2
groups under thermoneutral (TN) conditions. The role of
BAT in whole-body glucose metabolism is likely more read-
ily discerned when BAT is activated. Furthermore, Ouellet
et al. (12) demonstrated that BAT minimally contributed to
whole-body plasma glucose utilization, which might be due
to the shorter duration of CE and the presence of mild
shivering. Animal studies (8) suggest that BAT first con-
sumes intracellular energy stores before using plasma-
borne substrates to support its energy needs. Subsequently,
a longer CE may be necessary to elucidate the role of BAT
activation in plasma glucose disposal and oxidation in
humans.
The aim of this study was to investigate the effect of
prolonged (5–8 h) cold-induced BAT activation on the
whole-body glucose metabolism. Twelve men (7 BAT+ and
5 BAT2) were studied under CE and TN conditions. CE
increased resting energy expenditure (REE), plasma glucose
oxidation, and whole-body insulin-stimulated glucose dis-
posal in the BAT+ individuals only. The current data sup-
port a physiologically significant role for BAT in whole-body
glucose homeostasis and insulin sensitivity in humans.
RESEARCH DESIGN AND METHODS
Subjects
Twelve males participated in the study. The participants
were screened for health status, smoking, alcohol or drug
use, and recent medication or supplement use. Only healthy
individuals qualified to participate in the study. Informed
written consent was obtained from all participants prior to
their inclusion in the study in accordance with the
Declaration of Helsinki. The University of Texas Medical
Branch and Institute for Translational Sciences Institutional
Review Boards approved the experimental protocol.
Experimental Protocol
Each participant completed one CE study and one TN
study, 2 weeks apart (Fig. 1). The CE trial was performed
first to determine BAT volume and anatomical location
using 2-deoxy-2-[18F]-fluoro-D-glucose (18F-FDG) positron
emission tomography (PET)/computed tomography (CT)
scanning.
Three days before each study, subjects followed a weight-
maintaining diet and refrained from physical activity and
the consumption of alcohol and caffeine. The evening
before the study, subjects were admitted to the Institute
for Translational Sciences-Clinical Research Center at the
University of Texas Medical Branch. Patients were fed
a standardized evening meal. During CE and TN studies,
subjects were fasted overnight and remained rested in bed
for the duration of the study. Subjects wore standardized
clothing (T-shirt and shorts).
CE Protocol and TN Conditions
We used the following individualized CE protocol to
maximize nonshivering thermogenesis; subjects were stud-
ied in a room with an ambient temperature of ;19°C and
wearing garments cooled by liquid circulation (Cool Flow
vest and blanket; Polar Products Inc., Stow, Ohio). The
temperature of the vest was initially set at 20°C, then
decreased at 1°C intervals through an air-conditioned
temperature control bath (Chiller Reservoir System; Polar
Products Inc.) until subjects reported shivering. Then the
temperature was increased by 1°C and was maintained at
a constant temperature. We visually inspected the sub-
jects for shivering. In a subset of individuals (n = 3), we
performed electromyography (Bagnoli 8; Delsys, Boston,
MA) at 5-min intervals to verify muscle activity (14). Core
temperature and skin temperature were measured using
a telemetric pill (Core-Temp; HQ Inc., Palmetto, FL) and
wireless probes (iButtons; Maxim Integrated Products,
Dallas, TX) (15), respectively.
Stable Isotope Infusion
After 3 h of either the CE or the TN study, blood was
sampled to determine background enrichment, prior to
the administration of the following stable isotope tracers
(Cambridge Isotope Laboratories, Andover, MA) through
a catheter in the forearm vein, as follows: 1) a primed
(17.6 mmol/kg), constant (0.22 mmol/kg/min) 2-h infu-
sion of [6,6-2H2]-glucose to assess glucose kinetics (16); 2)
a constant 2-h infusion of potassium [U-13C16]-palmitate
(0.02 mmol/kg/min) to assess FFA kinetics (17,18); and 3)
a bolus of NaH13CO3 (55 mmol/kg dissolved in 0.9%
NaCl) was also given to prime the body’s bicarbonate
pool. Blood and breath samples were obtained at 1 h
and 50 min, 1 h and 55 min, and 2 h after the initiation
of the stable isotope infusion to determine isotopic
enrichments of plasma glucose and palmitate, and breath
CO2, and to measure substrate concentrations. The same
regimen, including only [6,6-2H2]-glucose, was repeated
during the hyperinsulinemic-euglycemic clamp. Whole-
body glucose disposal and FFA oxidation were calculated
as previously described (19,20). Changes between CE and
TN in glucose uptake were calculated as the difference
between the glucose uptake in CE and TN conditions.
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Hyperinsulinemic-Euglycemic Clamp
Hyperinsulinemic-euglycemic clamps were conducted dur-
ing the last 2 h of each trial, as previously described (21).
Insulin (Lilly, Indianapolis, IN) was administered at a rate
of 20 mU/m2/min, dissolved in sterile NaCl 0.9% (19). We
used a low insulin infusion rate to avoid the stimulation
of muscle plasma glucose disposal (22). Whole-body
insulin-stimulated glucose disposal was evaluated using
the insulin sensitivity index (23) and the following formula:
glucose disposal (in micromoles per kilogram per minutes)/
steady-state plasma glucose (in milligrams per deciliter) (24).
PET/CT Scanning
After 5 h, subjects were injected with a bolus of 185 MBq
18F-FDG. We performed a PET/CT scan (GE Discovery ST
4 Slice scanner; General Electric, Milwaukee, WI) an hour
later to assess BAT volume and BAT glucose disposal (BAT
volume [in milliliters] 3 mean standardized disposal
value [SUV; in grams per milliliter]). An independent
blinded investigator assessed the PET/CT scans for BAT,
as previously described (12). Subjects with pronounced
18F-FDG disposal were assigned to the BAT+ group (n =
7; BAT volume 696 18 mL) (Supplementary Fig. 1), while
subjects with no or minimal 18F-FDG disposal were
assigned to the BAT2 group (n = 5; BAT volume 4.4 6
2.3 mL; P , 0.05) (Supplementary Fig. 2).
Body Composition
DEXA (Lunar iDXA*; GE Healthcare, Mickleton, NJ)
was used to evaluate the lean and fat body mass of the
participants. CT was used to estimate total, subcutaneous,
and visceral abdominal tissue area (25–27).
Indirect Calorimetry
REE was calculated using whole-body oxygen consump-
tion and carbon dioxide production rates measured by
indirect calorimetry (Vmax Encore; CareFusion Corpora-
tion, San Diego, CA) (28). Indirect calorimetry equipment
failed on two occasions (one BAT+ subject and one BAT2
subject).
Blood Samples Analysis
Plasma glucose concentrations were determined using an
automated glucose analyzer (Stat 2300; Yellow Spring
Instruments). Gas chromatography mass spectrometry
was used to quantify plasma enrichments of glucose and
palmitate (Agilent, Santa Clara, CA). Plasma insulin and
free triiodothyronine (FT3) concentrations were measured
using chemiluminescence (Dxi 600 analyzer; Beckman
Coulter, Pasadena, CA). Free thyroxine (FT4) was measured
via a quantitative electrochemiluminescent immunoassay
(ARUP, Salt Lake City, UT). Plasma norepinephrine level
was determined using quantitative high-performance liq-
uid chromatography (ARUP, Salt Lake City, UT). Further,
serum interleukin-6 (IL-6) (R&D Systems, Minneapolis,
MN), plasma irisin (Phoenix Pharmaceuticals, Burlingame,
CA), and fibroblast growth factor 21 (FGF21) (BioVendor,
Asheville, NC) concentrations were determined using com-
mercially available ELISA kits.
Figure 1—Study design. The following tracers infused: [6,6-2H2]-glucose, [U-
13C16] palmitate, and
13C sodium bicarbonate. IC, indirect
calorimetry.
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Adipose Tissue Sampling
During CE, adipose tissue samples from the supraclavic-
ular and abdominal areas were obtained using a Bergström
needle. In a subset of individuals (three BAT+ and one
BAT2 individuals), biopsy samples were obtained during
both the CE and TN trials. The location for the supra-
clavicular biopsy was determined by the 18F-FDG PET/CT
scan images showing cold-activated BAT. In BAT2 indi-
viduals, the supraclavicular depot was sampled 2–3 cm
from the skin surface area, which is the same depth
that the BAT depot has been localized in BAT+ individuals.
Each sample was divided into pieces for the analyses de-
scribed below.
Immunohistochemistry
Adipose tissue, preserved in 10% formalin, was embedded
in paraffin wax. Immunohistochemistry was performed
using a standard protocol (29). Briefly, after blocking (Rab-
bit IgG kit; Vector Laboratories, Burlingame, CA) for 45
min, sections were incubated overnight with primary anti-
body (1:1,600, rabbit anti-UCP1 antibody, U6382; Sigma-
Aldrich) at 4°C. Sections were incubated with secondary
antibody (rabbit IgG; Vector Laboratories), ABC solution,
and then a diaminobenzidine solution (DAB peroxidase
substrate kit; Vector Laboratories) at room temperature.
Mitochondrial Respiration
Mitochondrial function was determined by high-resolution
respirometry (30). Briefly, maximal uncoupled mitochon-
drial respiration was measured in permeabilized (5 mmol/L
digitonin) WAT (;50 mg) and BAT (;10 mg) after the
addition of substrates (1.5 mmol/L octanoyl-carnitine, 5
mmol/L pyruvate, 10 mmol/L glutamate, 2 mmol/L malate,
5 mmol/L ADP, and 10 mmol/L succinate) and the ATP
synthase inhibitor oligomycin (5 mmol/L).
Gene Expression
Total RNA was isolated, and cDNA was synthesized and
analyzed by quantitative real-time PCR, as previously
described (2), using gene-specific primers at a final con-
centration of 300 nmol/L (Supplementary Table 2). 18S
was used as the normalizing gene and an established
supraclavicular BAT sample was included as a positive
control for BAT (2).
Statistical Analysis
Results are presented as means 6 SEM/SD. Differences
between CE and TN trials were evaluated using paired
t tests for normally distributed data. Non-normally distrib-
uted data were evaluated using a Wilcoxon rank sum test. A
one-sample t test was used to evaluate whether CE induced
changes in the various metabolic measurements compared
with TN. Differences between BAT2 and BAT+ subjects
were evaluated using a Mann-Whitney U test.
To evaluate differences in the circulating levels of
the various hormones/cytokines, we used a mixed ANOVA
model. Treatment differences (CE-TN) in the levels of
hormones/cytokines were determined for each subject at
each time point, accounting for the paired within-subject
correlation between treatments. A mixed ANOVA mod-
eled the differences as a function of time and BAT status,
an autoregressive model of order 1 correlation structure
accounted for by the within-subject repeated measures
over time, and a weighting structure adjusted for hetero-
geneity of variance over time. Differences were transformed
as needed to better approximate normal distributions, with
results inverse transformed appropriately. Statistical anal-
yses were performed using GraphPad, version 5 (GraphPad
Software, La Jolla, CA) for the Mac OS X operating sys-
tem and R statistical software (R Core Team, 2013,
version 3.0.1). All statistical tests assumed a 95% level of
confidence.
RESULTS
By design, the BAT+ group had higher BAT volume and
activity (P , 0.05) than the BAT2 group, but they were
similar in age and anthropometric characteristics (Table
1). BAT+ individuals required slightly, but not signifi-
cantly, lower ambient and garment temperatures to reach
their nonshivering threshold (Supplementary Table 1). CE
decreased skin temperature in both groups (P , 0.05).
The BAT2 group had a marginally lower core temperature
during CE conditions compared with that during TN con-
ditions (P = 0.06).
BAT Activation Increases Energy Expenditure and
Plasma Substrate Oxidation
Indirect calorimetry and stable isotopes were used to
determine REE and substrate oxidation rates. CE in-
creased REE (15%) in the BAT+ group only (P , 0.05)
(Fig. 2A), suggesting that BAT activation increases REE
during nonshivering CE. The cold-induced increase in
REE in the BAT+ group was fueled primarily by plasma-
derived glucose and FFA oxidation (P , 0.05 for both)
(Fig. 2B and C). Plasma glucose and FFA contributed
;30% and 70%, respectively, to the observed increase
in REE in the BAT+ group. These data suggest that,
upon prolonged stimulation, BAT largely oxidizes plasma
substrates to support its energy demands. This finding
supports a role for BAT in the regulation of systemic
glucose and FFA metabolism.
Glucose Disposal During CE Occurs Primarily in BAT
18F-FDG uptake during CE increased significantly in BAT
(P , 0.05), but not in the liver, abdominal visceral adi-
pose tissue, abdominal subcutaneous adipose tissue, or
skeletal muscle (vastus lateralis and pectoralis) (Fig. 3).
Interestingly, the mean heart SUV decreased significantly
with CE in BAT+ subjects (P , 0.05). In agreement with
previous reports (11,12), our data suggest that mild CE
results in increased disposal of labeled glucose by BAT
only, with minimal or no effects in other tissues.
BAT Activation Increases Basal Whole-Body Glucose
Disposal
To determine the physiological significance of BAT activa-
tion on whole-body glucose metabolism, we assessed glucose
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kinetics during TN conditions and during prolonged (5 h)
CE. CE significantly increased whole-body glucose disposal
only in the BAT+ group (P , 0.05) (Table 2, Fig. 4A). The-
oretically, if BAT remained chronically active, it could dis-
pose ;23 g of glucose in 24 h. Combined with the PET/CT
scan data, showing that 18F-FDG uptake increased only in
BAT (Fig. 3), these data suggest that, when activated, BAT
has the ability to take up significant amounts of glucose
from the circulation, and therefore can play a significant
role in glycemic control.
BAT Activation Increases Insulin-Stimulated Whole-
Body Glucose Disposal
Under thermoneutrality, insulin infusion significantly
increased whole-body glucose disposal in both groups
(P , 0.05 for both) (Table 2). This increase reflects in-
creased glucose disposal in many tissues and indicates
that the two groups were sensitive to insulin in peripheral
tissues (i.e., skeletal muscle, WAT), even though the BAT2
group needed higher insulin levels to achieve the same
result (i.e., slightly less insulin sensitive). Further, insulin
infusion suppressed endogenous glucose production sim-
ilarly in both groups (P , 0.05), indicating that both
groups were sensitive to insulin at the level of the liver.
After establishing that both groups were responsive to
insulin, we determined the effect of cold-induced BAT
activation on glucose disposal during hyperinsulinemia
(resembling the postprandial state). To this end, we
infused insulin after 6 h of CE. Compared with the
insulin-induced increase in glucose disposal in thermo-
neutrality, CE further increased glucose disposal in the
BAT+ group only (P , 0.05) (Table 2, Fig. 4B). The results
were similar when the whole-body glucose disposal rates
were corrected for glucose levels (whole-body insulin sen-
sitivity index) (Fig. 4C) or in combination with insulin
concentration (insulin sensitivity index) (Fig. 4D). Finally,
hyperinsulinemia equally suppressed endogenous glucose
production in both groups under CE conditions (P ,
0.05). These findings suggest that BAT activation may
play a functional role in peripheral glucose disposal,
both in the postabsorptive and postprandial state.
BAT Status and Hormonal/Cytokine Response to Cold
Our study was not designed to examine the mechanisms
regulating the effect of BAT activation on glucose
metabolism. Nevertheless, we measured the levels of
FT3, FT4, FGF21, cytokines (irisin, leptin, IL-6), and
norepinephrine, which have been previously associated
with BAT activation (8,10,30,31). The BAT+ group dem-
onstrated higher increases in the circulating concentra-
tions of norepinephrine, FGF21, and FT3, when
compared with the BAT2 group (Fig. 5A–C). FT4, irisin,
and IL-6 levels were not significantly different between
the two groups (Fig. 5D–F).
Molecular and Functional Characterization of BAT
The assignment of subjects into the BAT+ and BAT2
groups was based on the cold-induced glucose uptake in
the supraclavicular region as assessed by PET/CT scan-
ning. The reason for the low supraclavicular glucose
Figure 2—The role of BAT in REE and substrate oxidation. A: REE upon CE and TN conditions in BAT+ subjects and BAT2 subjects. B:
Plasma glucose oxidation under CE and TN conditions in BAT+ and BAT2 subjects. C: Plasma FFA oxidation under CE and TN conditions
in BAT+ and BAT2 subjects. White bars, TN; black bars, CE. Data are mean 6 SEM. *P < 0.05, CE vs. TN.
Table 1—Subject characteristics
Parameters
BAT2
(n = 5)
BAT+
(n = 7)
Age (years) 49.8 6 7.3 41.2 6 5.3
BMI (kg/m) 30.0 6 2.8 28.2 6 1.5
BSA (m2) 2.1 6 0.1 2.0 6 0.1
Lean mass (kg) 58.8 6 3.4 58.3 6 3.7
Body fat (%) 32.3 6 22.7 31.3 6 3.2
Visceral adipose
tissue (cm2) 57.8 6 12.2 41.9 6 8.4
Subcutaneous adipose
tissue (cm2) 90.0 6 22.7 94.3 6 12.0
BAT volume (mL) 4.4 6 2.3 69.0 6 18.0*
BAT activity (BAT volume
[mL] 3 mean SUV [g/mL]) 9.3 6 4.4 153.2 6 42.6*
AUCglu (mg/dL) 296.3 6 15.6 248.5 6 25.6
Data are mean 6 SEM. AUCglu, glucose area under the curve;
BSA, body surface area. *P , 0.05.
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uptake in the BAT2 group could be due to the fact that
this group had less BAT. Alternatively, the BAT2 group
might have had comparable amounts of BAT, relative to
the BAT+ group, but was unable to activate it in response
to the cold stimulus used (i.e., their threshold for cold-
induced activation of BAT may have not been reached). To
address the question of whether BAT2 subjects had BAT
or not, we performed molecular and functional studies on
adipose tissue samples collected from the supraclavicular
depot by the guidance of the PET/CT scan images, and
compared them with abdominal subcutaneous adipose tis-
sue samples.
BAT+ subjects had UCP1-positive multilocular adipo-
cytes in the supraclavicular tissue (Fig. 6A), whereas the
corresponding tissue of the BAT2 subjects demonstrated
minimal UCP1 staining and was composed of largely uni-
locular adipocytes (Fig. 6B). The abdominal subcutaneous
adipose tissue samples were similar between the two
groups, comprising unilocular adipocytes with no UCP1
staining (Fig. 6C and D). Quantification of the UCP1
staining confirms these results (supraclavicular adipose
tissue BAT+ vs. BAT2, P = 0.06) (Fig. 6E). In agreement
with the results from the immunohistochemical analysis,
UCP1 gene expression was higher in the supraclavicular
adipose tissue from the BAT+ group relative to the BAT2
group (P = 0.06) (Fig. 6F) and at a similar level as in
a well-documented BAT control sample included in the
analysis. No UCP1 expression was detected in the abdom-
inal subcutaneous adipose tissue samples. The molecular
studies were complemented with functional studies show-
ing that the maximal uncoupled mitochondrial respiration
was significantly higher in the supraclavicular adipose tis-
sue compared with the subcutaneous abdominal adipose
tissue (P , 0.05) only in the BAT+ group (Fig. 6G). These
results show that only the supraclavicular adipose tissue
from the BAT+ group presents with features of BAT,
Table 2—Indices of whole-body glucose homeostasis under CE and TN conditions
Parameters
BAT2 (n = 5) BAT+ (n = 7)
TN CE TN CE
Basal conditions
Glucose (mg/mL) 90.0 6 7.9 94.0 6 3.4 93.4 6 2.0 89.5 6 3.2
Whole-body glucose disposal (mmol/kg/min) 9.4 6 0.7 9.7 6 0.6 10.2 6 0.5 11.6 6 0.2*
Insulin (mU/mL) 8.6 6 4.0 8.2 6 1.3 3.9 6 0.8† 3.8 6 1.0†
Hyperinsulinemic-euglycemic conditions
Glucose (mg/mL) 83.8 6 3.1 85.8 6 3.5 81.1 6 3.3 81.5 6 5.8
Whole-body glucose disposal (mmol/kg/min) 12.4 6 2.2‡ 12.8 6 1.8 13.0 6 0.9‡ 16.5 6 1.1*,‡
Endogenous glucose production (mmol/kg/min) 5.6 6 1.6 7.5 6 1.1 5.3 6 1.7 6.3 6 1.3
Suppression of endogenous glucose production (%) 259.7 6 9.4 248.2 6 6.9 262.4 6 12.5 259.1 6 9.1
Insulin (mU/mL) 33.5 6 4.3 31.0 6 6.7 18.2 6 2.0† 18.8 6 2.0
Data are mean 6 SEM. *P , 0.05, CE vs. TN conditions. †P , 0.05, BAT2 vs. BAT+ subjects. ‡P , 0.05, basal vs. hyperinsulinemic-
euglycemic conditions.
Figure 3—Mean SUV for glucose of various tissues during CE and TN conditions. SQAT, subcutaneous adipose tissue; VAT, visceral
adipose tissue; white bars, TN; black bars, CE. Data are mean 6 SEM. *P < 0.05, **P < 0.01, CE vs. TN.
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whereas this is not the case for the BAT2 group. Hence,
the low glucose uptake in the BAT2 group is due to a lower
BAT content rather than a failure to activate BAT.
To further examine how CE affects human BAT on
a molecular level, biopsy samples were taken under both
TN and CE conditions in a subset of BAT+ subjects. As
predicted by animal studies on bona fide BAT, CE induced
the expression of both UCP1 and DIO2 (type 2 deiodinase)
(Fig. 6H and I). In addition, CE induced the expres-
sion of ADRB3 (b3-adrenergic receptor) and PGC1a
(peroxisome proliferator–activated receptor g coactivator
1a) (Supplementary Figs. 3 and 4). Hence, CE appears to
trigger the expression of essential thermogenic genes in
humans. The expression of the GLUT1 gene increased
with CE in three of four subjects, while GLUT4 gene ex-
pression increased in two of four participants (Supple-
mentary Figs. 5 and 6).
DISCUSSION
We have shown a physiologically significant effect of BAT
activation on whole-body glucose disposal in humans,
supporting a functional role of BAT in glucose homeosta-
sis and insulin sensitivity in humans. Our data suggest
that ;70 mL of active BAT can clear significant amounts
of glucose from the circulation. This glucose is used to
support the cold-induced increase in REE in the BAT+
group. Further, this was accompanied by an increase in
peripheral insulin-stimulated glucose disposal in BAT+
individuals. Our data demonstrate a significant role for
BAT activation in altering glucose control and insulin sen-
sitivity in humans.
Plasma glucose oxidation accounted for ;30% of the
estimated increase in REE during CE in BAT+ subjects.
This estimate is consistent with results from animal stud-
ies (32). Plasma FFA oxidation was responsible for the
remaining 70% of the increase in REE. This is also in
agreement with animal data suggesting that FFAs repre-
sent the primary substrate oxidized by UCP1-positive mi-
tochondria (32). Our findings of significant plasma
substrate use by BAT upon activation are in contrast
with a recent report that BAT uses mainly intracellularly
stored triacylglycerols and very few, if any, plasma sub-
strates (12). This may be due to the short (2.5 h) duration
of CE in this study (12) compared with that in our
longer CE protocol (5 h). This supposition is supported
by rodent data, which indicate that BAT first exhausts
Figure 4—Effect of BAT on whole-body glucose disposal and insulin sensitivity. Change in whole-body glucose disposal under CE relative
to TN in basal condition (A) and during hyperinsulinemic-euglycemic clamp (B). C: Change in the insulin sensitivity index (ISI) for CE and TN.
D: Change in whole-body insulin sensitivity for CE relative to TN. Data are means 6 SEM. White bars, BAT2; black bars, BAT+. *P < 0.05
and **P < 0.01, significant change with CE vs. TN conditions. †P < 0.05, BAT+ vs. BAT2.
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intracellular stores before relying on plasma-borne sub-
strates to support its energy needs (8). Therefore, we be-
lieve that our results differ from those previously reported
(12) due to our CE protocol being two times longer. The
duration of CE should be a consideration for future studies
aimed at elucidating the role of BAT activation in human
metabolism.
BAT is an insulin-sensitive tissue (11). Moreover, because
humans spend a significant portion of the day in the post-
prandial state, we examined the effect of cold-induced BAT
activation during a hyperinsulinemia-euglycemia clamp to
simulate the postprandial state in a laboratory setting.
Hyperinsulinemia significantly increased whole-body glu-
cose disposal and insulin sensitivity in the BAT+ group
only. These results suggest that BAT activation may
modulate whole-body glucose metabolism in the post-
prandial state. Moreover, relative to the TN study, CE
improved indexes of insulin sensitivity in the BAT+ group
only, further supporting a role for BAT activation in
whole-body insulin sensitivity in humans.
Although we cannot exclude the contribution of indirect
pathways in the observed increase in the insulin-stimulated
whole-body glucose uptake, we believe that the increase
was due to BAT activation and not a systemic response to
CE. This is supported by the fact that hyperinsulinemia
during thermoneutrality increased whole-body glucose
uptake equally in both groups, whereas hyperinsulinemia
during CE increased glucose uptake only in the BAT+ group.
Moreover, we performed a low-dose insulin clamp to avoid
significant muscle glucose uptake. Further, it is unlikely
Figure 5—Change in plasma concentrations of hormones and cytokines with CE in BAT+ and BAT2 subjects. A: Change in plasma
norepinephrine levels with CE in BAT+ and BAT2 individuals. B: Change in plasma FGF21 concentrations with CE in BAT+ and BAT2
individuals. Change in plasma FT3 (C ) and plasma FT4 (D) concentrations with CE in BAT+ and BAT2 individuals. E: Change in plasma
irisin concentration with CE in BAT+ and BAT2 individuals. F: Change in serum IL-6 concentrations with CE in BAT+ and BAT2 individuals.
Data are mean 6 SEM. *P < 0.05 and **P < 0.01, significant difference in response to CE between BAT+ and BAT2 subjects.
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that muscle glucose uptake was proceeding at a significant
rate, as CE causes peripheral vasoconstriction (33), which
has been shown to decrease peripheral insulin-stimulated
glucose uptake (34). Indeed, CE has been found to prefer-
entially enhance insulin signaling in BAT, and to perturb
insulin signaling in muscle and WAT (35), suggesting that
BAT is likely the tissue primarily responsible for the
reported improvements in insulin sensitivity during CE.
Norepinephrine also induces BAT activation by caus-
ing lipolysis (8). FFAs subsequently bind to and activate
UCP1, leading to mitochondrial thermogenesis (8). We
observed greater norepinephrine levels in response to CE
in the BAT+ subjects, which was likely responsible for the
increase in REE observed in the BAT+ group. Moreover,
norepinephrine production can stimulate BAT to pro-
duce FGF21 (36). FGF21 improves glucose homeostasis
Figure 6—Molecular and functional characterization of supraclavicular and abdominal subcutaneous adipose tissue samples in BAT+ and
BAT2 subjects under conditions of cold-induced BAT. UCP1 staining (340) in the supraclavicular (A and B) and abdominal (ABD) sub-
cutaneous (C and D) adipose tissue samples from representative BAT+ (A and C) and BAT2 (B and D) participants. E: Quantification of
UCP1 staining in supraclavicular (SC) and ABD subcutaneous adipose tissue. F: UCP1 gene expression in SC and ABD subcutaneous
adipose tissue. G: Uncoupled mitochondrial respiration in SC and ABD subcutaneous adipose tissue. Data are mean6 SEM. White circles,
BAT2; black circles, BAT+. *P < 0.05. H: UCP1 gene expression in BAT under TN and CE conditions. Data are mean 6 SD. ***P < 0.005. I:
DIO2 gene expression in BAT under TN and CE conditions. Data are mean 6 SD. ***P < 0.005.
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and insulin sensitivity by increasing GLUT1 expression
in WAT. A number of animal studies (8,10) and a few re-
cent humans studies support a role for BAT as an endo-
crine tissue (37). In agreement with this, CE induced
greater increases in circulating levels of FT3, norepineph-
rine, and FGF21 in the BAT+ group compared with the
BAT2 group in the current study. Thus, the reported im-
provement in insulin sensitivity in BAT+ subjects may be
attributable to circulating levels of FGF21 during CE. Ad-
renergic stimulation and FT3 are upstream regulators of
FGF21 production. Therefore, the concomitant increase in
FT3 and norepinephrine levels highlights a plausible path-
way by which BAT may function as an endocrine organ.
Specifically, CE increases DIO2 activity in BAT, resulting in
an acceleration in the conversion of thyroxin to triiodothy-
ronine, the active form of thyroid hormone (38). Indeed,
our results also show increased DIO2 expression in BAT
upon CE. In mice, triiodothyronine stimulates the sympa-
thetic nervous system, leading to higher UCP1 expression
in BAT (30).
The strengths of this study include the use of an
individualized, prolonged nonshivering CE protocol to elicit
maximal nonshivering thermogenesis and BAT activation,
along with the use of gold standard direct measures of whole-
body glucose metabolism in individuals with or without
active BAT depots. Although the methodological approaches
available and the restrictions governing human research
limit our ability to provide more direct and mechanistic
evidence, the results of this study strongly support the idea
that BAT activation plays a physiologically significant role in
whole-body glucose and energy metabolism in humans. The
use of invasive methodologies to directly measure substrate
metabolism and collect supraclavicular biopsy samples from
human volunteers allow physiologically meaningful conclu-
sions to be made.
In conclusion, our results suggest that BAT activation
increases whole-body glucose disposal and insulin sensitiv-
ity in humans. These results support a functional role of
BAT in whole-body glucose and energy homeostasis. Future
research is needed to further investigate the effect of
chronic BAT activation and the mechanisms underlying
BAT activation in humans to identify safe and efficacious
lifestyle or pharmaceutical interventions that may activate
BAT in vivo or induce the “browning” of the more abun-
dant WAT. If the potential of UCP1-positive adipocytes to
alter energy metabolism and expenditure in humans can be
fully realized, BAT will likely emerge as a therapeutic target
in the battle against obesity and diabetes.
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